ethylcholine aziridinium has been researched along with vasoactive intestinal peptide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardea, A; Brenneman, DE; Fridkin, M; Gozes, I; Reshef, A; Rubinraut, S; Zamostiano, R; Zhukovsky, S | 1 |
| Bachar, M; Bardea, A; Davidson, A; Fridkin, M; Gozes, I; Rubinraut, S | 1 |
2 other study(ies) available for ethylcholine aziridinium and vasoactive intestinal peptide
| Article | Year |
|---|---|
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aziridines; Cell Death; Cells, Cultured; Choline; Learning; Lipids; Male; Memory; Neuromuscular Blocking Agents; Neurons; Parasympatholytics; Rats; Rats, Wistar; Solubility; Structure-Activity Relationship; Vasoactive Intestinal Peptide | 1996 |
Protection against developmental deficiencies by a lipophilic VIP analogue.
Topics: Aging; Animals; Aziridines; Choline; Hypoxia; Intellectual Disability; Male; Maze Learning; Memory; Neuromuscular Blocking Agents; Neurotoxins; Rats; Space Perception; Vasoactive Intestinal Peptide | 1998 |